ProAxsis will this week be presenting new data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference in Orlando, Florida.
The first abstract is entitled “Development of a ProteaseTag® lateral flow device for detection of active neutrophil elastase in the clinic”, and will be presented by Dr Darragh McCafferty between 11.50 and 13.50 on October 27th, 2016 in the New Therapies/Biomarkers session and between 16.00 and 18.00 on October 28th, 2016 in the Special Basic Science Poster Session. This is the first time that data will be presented on the company’s test being developed for rapid measurement of neutrophil elastase at point-of-care.
The second abstract highlights some of the advantages of using the company’s ProteaseTag® technology, based on the selectivity and stability of the inhibitors developed, and is entitled “NE Ultra – A Novel ProteaseTag® for the inhibition and detection of neutrophil elastase in biological samples”. This abstract will also be presented in both the New Therapies/Biomarkers and Special Basic Science Poster sessions.
Dr David Ribeiro, CEO of ProAxsis, said: “This is the 30th annual meeting of the North American Cystic Fibrosis Society, and the organisers expect more than 4000 healthcare professionals to be in attendance. ProAxsis is delighted to share further information about our ProteaseTag®technology with the cystic fibrosis community at this conference.”
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
To learn more about our ProteaseTag® technology, or for further information about measuring active protease biomarkers in biological samples, please visit www.proaxsis.com or contact email@example.com